ArticleMicrobiology spectrum2025
Development and validation of a machine learning-based diagnostic model for identifying nonneutropenic invasive pulmonary aspergillosis in suspected patients: a multicenter cohort study.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Research trends in COPD-associated invasive pulmonary aspergillosis over the past two decades: a bibliometric and topic modelling analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Machine learning for early screening of influenza A-associated invasive pulmonary aspergillosis in hospitalized patients: a real-world study.Frontiers in cellular and infection microbiology · 2026Article
- Beyond detection: quantitative interpretation ofFrontiers in cellular and infection microbiology · 2026Article
- Predicting Mortality in Intensive Care Unit Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) Using an Interpretable Machine Learning Model: A Retrospective Cohort Study.Canadian respiratory journal · 2026Article
- Concurrent pretreatment serum and BALF galactomannan positivity as a prognostic indicator in non-neutropenic invasive pulmonary aspergillosis without malignancy or solid organ transplantation: a retrospective cohort study.Frontiers in medicine · 2026Article
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
This study aims to develop and validate an optimized diagnostic model for nonneutropenic invasive pulmonary aspergillosis (IPA) among suspected cases. A cohort of 344 nonneutropenic suspected cases from 13 medical centers (August 2020 to February 2024) was analyzed. The cohort was divided into a training data set (70%) and a testing data set (30%) using stratified sampling based on the IPA diagnosis. Three machine learning models (a regularized logistic regression model, a support vector machine model, and a weighted ensemble model) were developed. SHapley Additive explanation (SHAP) method was used for model interpretation. Six predictor variables were finally selected: sputum IMPORTANCE: Although clinicians can screen out suspected cases through medical history inquiries, the diagnosis of nonneutropenic invasive pulmonary aspergillosis (IPA) from suspected cases remains a significant challenge. The study developed a novel diagnostic framework by integrating clinical parameters, imaging features, and laboratory biomarkers using machine learning techniques. The risk score, derived from SHapley Additive explanation values, exhibited a highly significant correlation with the predicted probability of the weighted ensemble model, demonstrating robust discrimination capacity and generalizability. The diagnostic model and risk score could assist in identifying nonneutropenic IPA from suspected cases independently of invasive procedures, thereby enhancing clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.